Literature DB >> 8772610

Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis.

M Couce1, T D O'Brien, A Moran, P C Roche, P C Butler.   

Abstract

A high proportion of patients with cystic fibrosis (CF) develop diabetes mellitus. In common with type II diabetes mellitus, diabetes mellitus in CF is characterized by a progressive decline in beta-cell function and an approximately 50% decline in beta-cell mass. It is not known whether islet amyloidosis (characteristic of type II diabetes mellitus) is present in diabetes mellitus complicating CF. To address this, pancreatic samples were obtained at autopsy from 9 control cases (without CF) and 41 cases of CF that were, in turn, subdivided into 13 nondiabetic, 12 borderline diabetic, and 16 diabetic cases based on clinical criteria. Islet amyloid was detected by light microscopy in 69% cases of CF with diabetes mellitus, 17% of cases with borderline diabetes mellitus, and none of the nondiabetic cases. Islet amyloid was not present in any of the control cases. Islet amyloidosis derived from islet amyloid polypeptide is a characteristic feature of diabetes mellitus in CF as well as type II diabetes mellitus.

Entities:  

Mesh:

Year:  1996        PMID: 8772610     DOI: 10.1210/jcem.81.3.8772610

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  33 in total

Review 1.  Understanding cystic-fibrosis-related diabetes: best thought of as insulin deficiency?

Authors:  Lee Dobson; Christopher D Sheldon; Andrew T Hattersley
Journal:  J R Soc Med       Date:  2004       Impact factor: 5.344

2.  Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide.

Authors:  J Janson; W C Soeller; P C Roche; R T Nelson; A J Torchia; D K Kreutter; P C Butler
Journal:  Proc Natl Acad Sci U S A       Date:  1996-07-09       Impact factor: 11.205

3.  Is Cystic Fibrosis-related Diabetes Reversible? New Data on CFTR Potentiation and Insulin Secretion.

Authors:  Andrew W Norris
Journal:  Am J Respir Crit Care Med       Date:  2019-02-01       Impact factor: 21.405

4.  The influence of genetics on cystic fibrosis phenotypes.

Authors:  Michael R Knowles; Mitchell Drumm
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

5.  A novel assay in vitro of human islet amyloid polypeptide amyloidogenesis and effects of insulin secretory vesicle peptides on amyloid formation.

Authors:  Y C Kudva; C Mueske; P C Butler; N L Eberhardt
Journal:  Biochem J       Date:  1998-05-01       Impact factor: 3.857

6.  Genetic Modifiers of Cystic Fibrosis-Related Diabetes Have Extensive Overlap With Type 2 Diabetes and Related Traits.

Authors:  Melis A Aksit; Rhonda G Pace; Briana Vecchio-Pagán; Hua Ling; Johanna M Rommens; Pierre-Yves Boelle; Loic Guillot; Karen S Raraigh; Elizabeth Pugh; Peng Zhang; Lisa J Strug; Mitch L Drumm; Michael R Knowles; Garry R Cutting; Harriet Corvol; Scott M Blackman
Journal:  J Clin Endocrinol Metab       Date:  2020-05-01       Impact factor: 5.958

7.  Cystic fibrosis-related diabetes: from CFTR dysfunction to oxidative stress.

Authors:  Thierry Ntimbane; Blandine Comte; Geneviève Mailhot; Yves Berthiaume; Vincent Poitout; Marc Prentki; Rémi Rabasa-Lhoret; Emile Levy
Journal:  Clin Biochem Rev       Date:  2009-11

Review 8.  The Clinical Biology of Cystic Fibrosis Transmembrane Regulator Protein: Its Role and Function in Extrapulmonary Disease.

Authors:  Theodore G Liou
Journal:  Chest       Date:  2018-10-22       Impact factor: 9.410

Review 9.  Epidemiology, pathophysiology, and prognostic implications of cystic fibrosis-related diabetes: a technical review.

Authors:  Antoinette Moran; Dorothy Becker; Samuel J Casella; Peter A Gottlieb; M Sue Kirkman; Bruce C Marshall; Bonnie Slovis
Journal:  Diabetes Care       Date:  2010-12       Impact factor: 19.112

Review 10.  Endocrine Disorders in Cystic Fibrosis.

Authors:  Scott M Blackman; Vin Tangpricha
Journal:  Pediatr Clin North Am       Date:  2016-08       Impact factor: 3.278

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.